156779-11-2 Usage
Description
Methyl 1-Benzyl-6-oxopiperidine-3-carboxylate is a chemical compound characterized by its molecular formula C17H21NO3. It is a white crystalline powder with a molecular weight of 287.35 g/mol. Methyl 1-Benzyl-6-oxopiperidine-3-carboxylate is widely recognized for its role in organic synthesis and as a key intermediate in the production of pharmaceuticals and agrochemicals. Its potential as a building block in the synthesis of various bioactive compounds underscores its value within the pharmaceutical industry. However, it is crucial to handle this compound with care due to potential health hazards if not used properly.
Uses
Used in Pharmaceutical Industry:
Methyl 1-Benzyl-6-oxopiperidine-3-carboxylate is used as a key intermediate for the synthesis of various pharmaceuticals. Its role in the creation of bioactive compounds makes it an essential component in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical sector, Methyl 1-Benzyl-6-oxopiperidine-3-carboxylate is utilized as an intermediate in the production of agrochemicals, contributing to the development of effective and innovative products for agricultural applications.
Organic Synthesis:
Methyl 1-Benzyl-6-oxopiperidine-3-carboxylate is used as a building block in organic synthesis, facilitating the creation of a range of chemical compounds with diverse applications across various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 156779-11-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,7,7 and 9 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 156779-11:
(8*1)+(7*5)+(6*6)+(5*7)+(4*7)+(3*9)+(2*1)+(1*1)=172
172 % 10 = 2
So 156779-11-2 is a valid CAS Registry Number.
156779-11-2Relevant articles and documents
ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
-
Page/Page column 453; 454, (2018/09/21)
Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.
Synthesis and reduction reactions of pyridones and 5-acyl-2-methoxypyridines
Bisset, Alexander A.,Dishington, Allan,Jones, Teyrnon,Clarkson, Guy J.,Wills, Martin
, p. 7207 - 7220 (2017/09/12)
The synthesis of a series of pyridones, from their 2-hydroxypyridine or 2-methoxypyridine precursors, is described, along with studies into their reductions to saturated heterocycles. A number of 5-acylpyridones were prepared and were evaluated as substrates for asymmetric transfer hydrogenation prior to conversion to saturated heterocycles. The enantioselective reduction of 5-acetyl-1-benzylpyrimidine-2,4(1H,3H)-dione is also described.
An efficient synthetic route to functionalized δ-lactams
Samarat, Ali,Ben Kra?em, Jihène,Ben Ayed, Ta?cir,Amri, Hassen
, p. 9540 - 9543 (2008/12/22)
This paper describes a convenient synthesis of disubstituted functionalized δ-lactams based on Michael addition of primary amines to dimethyl-E-2-alkylidene glutarates 2 followed by an intramolecular cyclisation.
